Pharmaceutical News

RSS

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

GLP-1 obesity drugs mainly reduce fat while preserving muscle mass

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following treatment with GLP-1 drugs for obesity, most weight loss is fat mass (80–85%) and relative muscle mass is preserved.

13 May 2026

Expert questions benefits of new UK drug approval pathway

A new UK drug approval pathway, designed to speed up the availability of new medicines, benefits industry over patients and the NHS, argues an expert in The BMJ today.

13 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026

A century of safety: Aluminium vaccine adjuvants do not raise serious long-term health risks

A BMJ systematic review of 59 human studies found no evidence supporting causal links between aluminum-adjuvanted vaccines and serious or long-term outcomes such as autism spectrum disorder, asthma, autoimmune conditions, or other chronic illnesses. The most consistent adverse events were uncommon, local, self-limited persistent nodules or granulomas, likely reflecting delayed-type hypersensitivity.

11 May 2026

Study compares two antibiotics in treating severe hemorrhagic bacterial pneumonia

Stenotrophomonas maltophilia (S. maltophilia) is a multidrug-resistant bacterium that can cause severe and life-threatening hemorrhagic pneumonia in individuals with weakened immune systems.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Greater weight loss from GLP-1 drugs lowers health complication risk

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, following treatment for obesity or diabetes or both using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to relatively lower risk of obesity-related conditions.

10 May 2026

Liver fat may disrupt post-meal glucagon control in early type 2 diabetes

Researchers found that MASLD, rather than type 2 diabetes alone, was linked to higher fasting glucagon levels in adults with newly diagnosed diabetes and matched controls. In people with early type 2 diabetes, higher liver fat was specifically associated with exaggerated early post-meal glucagon responses, independent of insulin sensitivity, visceral fat, amino acids, or NEFAs.

10 May 2026

Asthma medication formoterol shows promise for treating fatty liver disease

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.

8 May 2026

GLP-1 drugs may reshape how brain values rewarding foods

A new study from the University of Virginia reveals that a widely used class of weight-loss drugs does more than suppress appetite-it directly alters brain circuits that control motivation and reward.

6 May 2026

CGRP inhibitors may reduce glaucoma risk among migraine patients

A type of drug used to prevent migraine may be associated with a reduced risk of glaucoma, according to a study published May 6, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

6 May 2026

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

GLP-1 use surges as surgery rates drop for severe obesity

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially -- from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 -- according to a new real-world analysis presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Study highlights stigma surrounding popular GLP-1 weight loss drugs

Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss.

4 May 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026

GLP-1 drugs reduce risk of major adverse cardiovascular events

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

30 Apr 2026